Impact of new antifungal breakpoints on antifungal resistance in Candida species

Annette W. Fothergill, Deanna A. Sutton, Dora I. McCarthy, Nathan P. Wiederhold

Research output: Contribution to journalArticle

56 Scopus citations

Abstract

We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).

Original languageEnglish (US)
Pages (from-to)994-997
Number of pages4
JournalJournal of clinical microbiology
Volume52
Issue number3
DOIs
StatePublished - Mar 2014

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Impact of new antifungal breakpoints on antifungal resistance in Candida species'. Together they form a unique fingerprint.

  • Cite this